Rosetta Genomics (ROSG) Announces NY State Approval for miRview Lung

Rosetta Genomics (NASDAQ: ROSG) announced that the New York State Department of Health has given the Company conditional approval for its miRview lung assay for testing on patient samples from the State. New York is the only U.S. state that requires an independent regulatory review process for laboratory-developed tests. With this approval, Rosetta Genomics can offer miRview lung in all 50 U.S. states. In making the assay available pending final approval, the NYSDOH requires the Company to provide any additional information they request within 60 business days. miRview lung is the Company's proprietary microRNA-based assay that accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• loanDepot receives NYSE non-compliance notice over stock price
• Hinge Health signs $86M office lease in San Francisco